Starbucks CEO Brian Niccol on menu changes amid GLP-1 weight-loss drug trend

Bullish Gator

Niccol says Starbucks is shifting to smaller, protein-focused meals in response to the rise of GLP-1 weight-loss drugs.

Editorial companion

What stands out

Starbucks CEO Brian Niccol said the company is shifting toward smaller, more protein-focused meals in response to the rise of GLP-1 weight-loss drugs, putting menu strategy squarely in front of a structural change in how people eat. The remark matters because a national coffee chain repositioning core food items is a practical response to changing calories and appetite, not just a marketing line. Niccol framed the move as product-level adaptation rather than store closings or price changes, making the conversation concrete and operational.